Development of short-term potentiation (STP) of respiration, which leads to the respiratory 'afterdischarge', was studied in anesthetized, paralyzed, vagotomized and glomectomized cats. Phrenic nerve activity was used as an index of respiratory output. Respiratory output was increased and the potentiating mechanism activated by electrical stimulation of a carotid sinus nerve (CSN). Development of STP was determined from the magnitude of potentiation after various durations (0 to 60 sec) of stimulation. The average time constant (TC) for the development of the potentiation was 9 sec, whereas the TC for its decay (afterdischarge) was 46.1 +/- 3.9 sec. The magnitude of potentiation is dependent upon the number of pulses in the stimulus train. We conclude that the development of short-term potentiation of respiration is relatively slow but much faster than the decay, or afterdischarge. We suggest that the slow increase of respiration during a stimulation and the decay afterwards are due to a common mechanism, short-term potentiation of neural activity in respiratory control pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0034-5687(91)90098-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The purpose of this study was to investigate whether circulating pyruvate kinase M2 (PK-M2) levels are elevated in the peripheral blood and to assess their association with diagnosis and prognosis in patients with heart failure (HF).
Methods And Results: We conducted a prospective investigation involving 222 patients with HF and 103 control subjects, measuring PK-M2 concentrations using ELISA. The primary outcome, assessed over a median follow-up of 2 years (interquartile range: 776 to 926 days), was the time to the first occurrence of either rehospitalization for worsening HF or cardiovascular death.
Predictive Role of Soluble B-Cell Maturation Antigen in Short-Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study.
J Clin Lab Anal
January 2025
Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Background: The management of multiple myeloma is challenging because the disease is incurable and unexpected relapses can threaten a patient's survival. Several assessment systems are currently available, but they often require invasive or costly procedures (e.g.
View Article and Find Full Text PDFA retrospective study assessing RefluxStop surgery for gastroesophageal reflux disease: Clinical outcomes in 79 patients from Germany.
Surg Open Sci
January 2025
Klinikum Friedrichshafen GmbH, Department of Visceral Surgery, Röntgenstraße 2, 88048 Friedrichshafen, Germany.
Background: This study reports outcomes of the RefluxStop procedure treating gastroesophageal reflux disease (GERD) in clinical practice at a high-volume regional hospital in Germany.
Methods: A retrospective analysis was conducted on 79 patients with chronic GERD that underwent the RefluxStop procedure, comprising high mediastinal dissection, loose cruroplasty, esophagogastroplication between vagal trunks, and fundus invagination of the RefluxStop implant. The primary outcome was GERD Health-Related Quality-of-Life (GERD-HRQL) score and improvement from baseline.
Revisiting the unobtrusive role of exogenous stem cells beyond neural circuits replacement in spinal cord injury repair.
Theranostics
January 2025
Department of biochemistry and molecular biology, College of Life Sciences, Central South University, Changsha, 410078, Hunan, China.
Stem cell transplantation is a promising strategy to establish neural relays in situ for spinal cord injury (SCI) repair. Recent research has reported short-term survival of exogenous cells, irrespective of immunosuppressive drugs (ISD), results in similar function recovery, though the mechanisms remain unclear. This study aims to validate this short-term repair effect and the potential mechanisms in large animals.
View Article and Find Full Text PDFThe Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review.
Ther Clin Risk Manag
January 2025
Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. Oral selexipag is effective, but may be discontinued due to factors like side effects, emergency conditions, or inability to take oral medication, potentially leading to severe adverse events, such as rebound pulmonary hypertension and right heart failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!